Axsome Therapeutics slides as investors weigh launch execution and policy risks

Axsome Therapeutics (AXSM) is down 4.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is a mix of profit-taking and renewed scrutiny around Axsome’s valuation after a recent analyst price-target cut. This could also be because investors are reassessing how quickly Auvelity’s new Alzheimer’s agitation launch can scale, while broader pharmaceutical policy and tariff concerns add another layer of uncertainty.

Details:

Axsome’s latest quarterly update showed strong top-line growth, with second-quarter 2026 net product revenue of $218.4 million, but the company still posted a net loss as selling and marketing costs climbed with commercialization efforts.

Auvelity sales reached $180.3 million in the quarter, and the company highlighted an early launch benefit in Alzheimer’s disease agitation, but investors may be debating how durable that uptake will be and how access or patient-cost issues could affect adoption.

A recent analyst update kept a neutral-style rating in place while trimming the price target to $247 from $251, signaling a more measured view after the stock’s earlier run.

Axsome’s 10-Q also flagged evolving U.S. pharmaceutical tariff and pricing policy as a risk factor, even though the company said it does not currently expect a material impact on operations.

Sources:

Axsome Therapeutics, SEC, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$AXSM Insider Trading Activity

$AXSM insiders have traded $AXSM stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $AXSM stock by insiders over the last 6 months:

HERRIOT TABUTEAU (Chief Executive Officer) has made 0 purchases and 4 sales selling 149,000 shares for an estimated $34,441,528.
NICK PIZZIE (Chief Financial Officer) sold 33,000 shares for an estimated $7,922,970
MARK COLEMAN has made 0 purchases and 4 sales selling 18,180 shares for an estimated $4,179,577.
MARK L. JACOBSON (Chief Operating Officer) has made 0 purchases and 3 sales selling 14,750 shares for an estimated $3,169,270.
ARI MAIZEL (Chief Commercial Officer) sold 7,500 shares for an estimated $1,368,150
SUSAN MAHONY has made 0 purchases and 2 sales selling 600 shares for an estimated $145,017.
ROGER JEFFS has made 0 purchases and 2 sales selling 572 shares for an estimated $141,655.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$AXSM Hedge Fund Activity

We have seen 295 institutional investors add shares of $AXSM stock to their portfolio, and 214 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

RTW INVESTMENTS, LP removed 888,001 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $150,089,929
BLACKROCK, INC. removed 809,136 shares (-20.7%) from their portfolio in Q2 2026, for an estimated $198,052,218
PRICE T ROWE ASSOCIATES INC /MD/ removed 674,166 shares (-51.2%) from their portfolio in Q2 2026, for an estimated $165,015,611
MILLENNIUM MANAGEMENT LLC added 535,330 shares (+2578.9%) to their portfolio in Q2 2026, for an estimated $131,032,724
WELLINGTON MANAGEMENT GROUP LLP removed 491,386 shares (-42.9%) from their portfolio in Q2 2026, for an estimated $120,276,551
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 478,544 shares (-64.9%) from their portfolio in Q2 2026, for an estimated $117,133,214
DEEP TRACK CAPITAL, LP removed 400,000 shares (-36.4%) from their portfolio in Q2 2026, for an estimated $97,908,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$AXSM Price Targets

Multiple analysts have issued price targets for $AXSM recently. We have seen 11 analysts offer price targets for $AXSM in the last 6 months, with a median target of $267.0.

Here are some recent targets:

Raghuram Selvaraju from HC Wainwright & Co. set a target price of $290.0 on 07/08/2026
Leonid Timashev from RBC Capital set a target price of $304.0 on 07/07/2026
Joseph Thome from TD Cowen set a target price of $300.0 on 06/17/2026
Ami Fadia from Needham set a target price of $267.0 on 05/05/2026
Joel Beatty from Baird set a target price of $246.0 on 05/05/2026
Benjamin Burnett from Wells Fargo set a target price of $255.0 on 05/05/2026
Yatin Suneja from Guggenheim set a target price of $260.0 on 05/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.